Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.
about
The role of gut endocrine cells in control of metabolism and appetiteLocal, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum.Upper gastrointestinal function and glycemic control in diabetes mellitus.Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesityGlucagon-like peptide-1 and-2 levels in children with diabetic ketoacidosisPhysiology of the aerodigestive system and aberrations in that system resulting in aspiration.Management of diabetic gastroparesis.Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans.Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.The pylorus.Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying.Gut-brain neuropeptides in the regulation of ingestive behaviors and obesity.Effect of Gongronema latifolium on gastric emptying in healthy dogs.Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes.Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial.Relationships between gastric emptying, postprandial glycemia, and incretin hormonesThe role of alginates in regulation of food intake and glycemia: a gastroenterological perspective.Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.Gut: A key player in the pathogenesis of type 2 diabetes?Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Effects of GLP-1 and incretin-based therapies on gastrointestinal motor functionEndogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion.Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans.Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions.Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans.Video-based spatio-temporal maps for analysis of gastric motility in vitro: effects of vagal stimulation in guinea-pigs.Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans.Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length.Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men.Intestinal motor activity, endoluminal motion and transit.Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction.Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
P2860
Q26824311-F0DE06CB-A9DA-4C0A-873F-D7050FF638C9Q33184111-1CF7E853-0883-434F-9AFD-649467183214Q33869207-E969AAD0-ABEA-4EC1-BFBF-E64EF57BD48EQ34310033-93BC11B0-D45E-45B0-BBFC-C63EC6E198A8Q34423035-A47A9338-D28A-415C-8198-B27146CE3BDFQ34983182-90E1D55B-0791-4D07-8717-FA903C3C8EBFQ34996050-8C62C4FC-D560-4F2E-AB19-9BD6B6461A73Q35493790-B18F3A8D-8BA9-4E29-9D9A-940DD7C7154BQ35567284-95551C44-D182-4CF4-8DC7-EFD3714235C6Q35612104-48DAAEF4-12C4-4085-820D-814159B9D548Q35772029-0333FD2F-382B-4F48-A523-7E3D8CC0A957Q36100737-720F6F33-7B5E-4115-A1A5-1274422121C0Q36302747-25E188F7-84E9-4A8C-9CA1-C39747730BD7Q36616593-39F551EC-70E6-402C-A642-92B40A965DFCQ36616827-2D374E01-3AA4-447A-8609-2824335ED68CQ36816194-0BCD5BE2-4AFC-4256-8102-730DB48A3696Q36877627-18DF97A6-A52F-49F8-A4D1-079223FCC6ECQ36882784-35C6BCE9-C9E4-4A84-AEB5-B6CC0B90D1BFQ37319106-BF4710D7-080A-4E73-9505-82DA57BD95A4Q38101324-EDB1AB92-881C-4A4B-9E0D-6FAA293B0BDFQ38219120-E5193F1D-78C2-4950-B8DD-A930D655AF24Q38340339-3A91CBD7-6952-496D-824D-76C5373830E6Q38616170-3579A7B1-4D6D-4FF6-AD14-91EC7F3FD08DQ39021924-904F76D6-5CD3-4A29-8CA0-0442F468F09BQ39047697-545771EE-CDAB-42D9-B62B-299361FDAF15Q42775479-48E98469-DD97-4CA9-B257-344CE1A52B88Q42844051-9DEB6234-5E88-4283-B719-C427C17AA095Q42911684-48A1688A-CACC-46FC-BFE5-0E3395629CEEQ43006439-F7CF89F6-926C-450E-95E8-91151047D183Q43292882-63B7C68B-2545-4710-BDE3-43A2AEB5F2E9Q43884231-DF6E47B0-D64B-41E0-9696-7D42FEFFF722Q43970914-1B66FE89-F200-49DE-B48E-C818EF5ECEF1Q44237261-25012B22-3756-447B-8FC0-8BC782728951Q44396038-BD2D2606-B56E-4955-95E9-471BD9363BA1Q44912774-B4BFDA0E-4E28-4D6F-ADA0-5435C8618B8DQ45253690-D9613D12-39C4-4B7D-84FD-0DEFFF5E7194Q45963586-760786DC-9D1F-43F4-99ED-1CD2D1F0A9D1Q47323757-7E9EF76C-F366-464E-AEDE-A8F269E647F9Q47778402-7D29E8EC-66F8-4B09-8D68-55A327B9580EQ48169180-A8DEFEB8-04A5-4FB1-82B2-82321BD6666F
P2860
Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@ast
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@en
type
label
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@ast
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@en
prefLabel
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@ast
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@en
P2093
P2860
P356
P1433
P1476
Effects of glucagon-like pepti ...... nal lipid perfusion in humans.
@en
P2093
P2860
P304
P356
10.1136/GUT.46.5.622
P407
P577
2000-05-01T00:00:00Z